<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Outpatient versus inpatient treatment for acute pulmonary embolism - Yoo, HHB - 2022 | Cochrane Library</title> <meta content="Outpatient versus inpatient treatment for acute pulmonary embolism - Yoo, HHB - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010019.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Outpatient versus inpatient treatment for acute pulmonary embolism - Yoo, HHB - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010019.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010019.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Outpatient versus inpatient treatment for acute pulmonary embolism" name="citation_title"/> <meta content="Hugo HB Yoo" name="citation_author"/> <meta content="Botucatu Medical School, São Paulo State University-UNESP" name="citation_author_institution"/> <meta content="hugo.yoo@unesp.br" name="citation_author_email"/> <meta content="Vania Santos Nunes-Nogueira" name="citation_author"/> <meta content="Botucatu Medical School, São Paulo State University-UNESP" name="citation_author_institution"/> <meta content="Paulo J Fortes Villas Boas" name="citation_author"/> <meta content="Botucatu Medical School, São Paulo State University-UNESP" name="citation_author_institution"/> <meta content="Cathryn Broderick" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD010019.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010019.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010019.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010019.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Hemorrhage [epidemiology, therapy]; Hospitalization; Inpatients; *Outpatients; *Pulmonary Embolism [therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010019.pub4&amp;doi=10.1002/14651858.CD010019.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010019\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010019\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","pt","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010019.pub4",title:"Outpatient versus inpatient treatment for acute pulmonary embolism",firstPublishedDate:"May 5, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010019.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010019.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010019.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010019.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010019.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010019.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010019.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010019.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010019.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010019.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4134 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010019.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-sec-0083"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-sec-0077"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/appendices#CD010019-sec-0088"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/supinfo/CD010019StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/supinfo/CD010019StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Outpatient versus inpatient treatment for acute pulmonary embolism</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information#CD010019-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Hugo HB Yoo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information#CD010019-cr-0005">Vania Santos Nunes-Nogueira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information#CD010019-cr-0006">Paulo J Fortes Villas Boas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information#CD010019-cr-0007">Cathryn Broderick</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information/en#CD010019-sec-0103">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010019.pub4">https://doi.org/10.1002/14651858.CD010019.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010019-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010019-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010019-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010019-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010019-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010019-abs-0004">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010019-abs-0001" lang="en"> <section id="CD010019-sec-0001"> <h3 class="title" id="CD010019-sec-0001">Background</h3> <p>Pulmonary embolism (PE) is a common life‐threatening cardiovascular condition, with an incidence of 23 to 69 new cases per 100,000 people each year. For selected low‐risk patients with acute PE, outpatient treatment might provide several advantages over traditional inpatient treatment, such as reduction of hospitalisations, substantial cost savings, and improvements in health‐related quality of life. This is an update of an earlier Cochrane Review. </p> </section> <section id="CD010019-sec-0002"> <h3 class="title" id="CD010019-sec-0002">Objectives</h3> <p>To assess the effects of outpatient versus inpatient treatment in low‐risk patients with acute PE. </p> </section> <section id="CD010019-sec-0003"> <h3 class="title" id="CD010019-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was 31 May 2021. </p> </section> <section id="CD010019-sec-0004"> <h3 class="title" id="CD010019-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of outpatient versus inpatient treatment of adults (aged 18 years and over) diagnosed with low‐risk acute PE. </p> </section> <section id="CD010019-sec-0005"> <h3 class="title" id="CD010019-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were short‐ and long‐term all‐cause mortality. Secondary outcomes were bleeding, adverse effects, recurrence of PE, and patient satisfaction. We used GRADE to assess certainty of evidence for each outcome. </p> </section> <section id="CD010019-sec-0006"> <h3 class="title" id="CD010019-sec-0006">Main results</h3> <p>We did not identify any new studies for this update. We included a total of two RCTs involving 453 participants. Both trials discharged participants randomised to the outpatient group within 36 hours of initial triage, and both followed participants for 90 days. One study compared the same treatment regimens in both outpatient and inpatient groups, and the other study used different treatment regimens. There was no clear difference in treatment effect for the outcomes of mortality at 30 days (risk ratio (RR) 0.33, 95% confidence interval (CI) 0.01 to 7.98; 2 studies, 453 participants; low‐certainty evidence), mortality at 90 days (RR 0.98, 95% CI 0.06 to 15.58; 2 studies, 451 participants; low‐certainty evidence), major bleeding at 14 days (RR 4.91, 95% CI 0.24 to 101.57; 2 studies, 445 participants; low‐certainty evidence) and at 90 days (RR 6.88, 95% CI 0.36 to 132.14; 2 studies, 445 participants; low‐certainty evidence), minor bleeding (RR 1.08, 95% CI 0.07 to 16.79; 1 study, 106 participants; low‐certainty evidence), recurrent PE within 90 days (RR 2.95, 95% CI 0.12 to 71.85; 2 studies, 445 participants; low‐certainty evidence), and patient satisfaction (RR 0.97, 95% CI 0.90 to 1.04; 2 studies, 444 participants; moderate‐certainty evidence). We downgraded the certainty of the evidence because the CIs were wide and included treatment effects in both directions, the sample sizes and numbers of events were small, and it was not possible to determine the effect of missing data or the presence of publication bias. The included studies did not assess PE‐related mortality or adverse effects, such as haemodynamic instability, or adherence to treatment. </p> </section> <section id="CD010019-sec-0007"> <h3 class="title" id="CD010019-sec-0007">Authors' conclusions</h3> <p>Currently, only low‐certainty evidence is available from two published randomised controlled trials on outpatient versus inpatient treatment in low‐risk patients with acute PE. The studies did not provide evidence of any clear difference between the interventions in overall mortality, bleeding, or recurrence of PE. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010019-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010019-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010019-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010019-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010019-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010019-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010019-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010019-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010019-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010019-abs-0002" lang="en"> <h3>Is home or hospital treatment better for people with blood clots in the lungs?</h3> <p><b>Key message</b> </p> <p>We are uncertain if treatment in hospital or at home (outpatient) is better for some people with blood clots in the lungs. We did not find clear evidence of an important difference in the number of deaths, bleeding, recurrence of new blood clots, or patient satisfaction, because the results were imprecise and the studies did not report side effects on blood pressure or information on how well people followed medical advice. More well‐designed studies are needed before doctors can make informed practice decisions. </p> <p><b>Why is this question important?</b> </p> <p>A blood clot in the lungs (pulmonary embolism) is a major cause of death and illness. These can occur after a blood clot breaks off from somewhere else in the body and travels in the blood to the lungs. The clot can often travel from the leg, where it is called a deep vein thrombosis. How people are treated depends on whether they are low‐risk or high‐risk, but most people are given blood‐thinning drugs (anticoagulants) in hospital. For some low‐risk cases with sudden onset (acute) pulmonary embolism, treatment at home might be better than keeping them in hospital. Possible benefits include fewer people in hospital, less risk of picking up an infection in hospital, cost savings, and better health‐related quality of life. We wanted to know if there were any differences in risks and benefits between people with blood clots in the lungs who are treated at home compared to those treated in the hospital. </p> <p><b>What did we do?</b> </p> <p>We searched for randomised controlled trials that treated adults with sudden onset, low‐risk, pulmonary embolism at home or in hospital. In randomised controlled trials, the treatments people receive are decided at random, and these types of studies give the most reliable evidence about treatment effects. </p> <p><b>What did we find?</b> </p> <p>We found two studies involving 453 people with sudden onset pulmonary embolism who were treated at home or in hospital. One study used the same treatment for the people treated at home or in hospital, and the second study used different treatments. We did not find any clear differences in the number of deaths, bleeding, new clots, or patient satisfaction between the groups of people who were treated at home or in the hospital. </p> <p>Neither study provided information on side effects of the treatment or on whether people were able to follow the correct instructions at home. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are not very certain about the evidence from the two included studies. This is because there were only small numbers of people in the studies (and small numbers of events) and because we could not be sure that reports of studies where no effect was shown were ever published. </p> <p><b>How up to date is this evidence?</b> </p> <p>This review updates our previous review. The evidence is up to date to May 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010019-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010019-sec-0083"></div> <h3 class="title" id="CD010019-sec-0084">Implications for practice</h3> <section id="CD010019-sec-0084"> <p>This review included two published randomised controlled trials comparing outpatient and inpatient treatment for acute pulmonary embolism in low‐risk patients. The evidence was of low certainty; the studies did not provide evidence of any clear difference between the treatment groups in overall mortality, bleeding, or recurrence of pulmonary embolism. </p> </section> <h3 class="title" id="CD010019-sec-0085">Implications for research</h3> <section id="CD010019-sec-0085"> <p>This review highlights the need for further research into inpatient versus outpatient treatment for acute pulmonary embolism and to determine which validated severity score(s) should be used to identify low‐risk pulmonary embolism. Future trials need to be adequately powered to increase the certainty of detecting a difference or to determine that there is no difference in treatments. Standardised outcome measures with adequate follow‐up, such as mortality, hospitalisation rates, health‐related quality of life, and costs are also required. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010019-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010019-sec-0008"></div> <div class="table" id="CD010019-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Outpatient versus inpatient treatment for acute pulmonary embolism</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Outpatient versus inpatient treatment for acute pulmonary embolism</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with low‐risk acute pulmonary embolism </p> <p><b>Settings</b>: outpatient and inpatient settings </p> <p><b>Intervention</b>: outpatient setting<sup>a</sup> </p> <p><b>Comparison</b>: inpatient setting<sup>b</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with inpatient setting</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with outpatient setting</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term all‐cause mortality</b> </p> <p>Follow‐up: 7 to 10 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred in either study within this time period.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Short‐term all‐cause mortality</b> </p> <p>Follow‐up: to 30 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 0.33 (0.01 to 7.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>453 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 1/168 deaths in the inpatient group vs 0/171 deaths in the outpatient group. The death reported by <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> was not PE‐related. No deaths occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000 (0 to 35)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Long‐term all‐cause mortality</b> </p> <p>Follow‐up: 90 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 0.98 (0.06 to 15.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>451<sup>e</sup> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 1/168 deaths in the inpatient group vs 1/171 deaths in the outpatient group. The deaths reported by <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> were not PE‐related. No deaths occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (0 to 68)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b> </p> <p>Follow‐up: 14 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 4.91 (0.24 to 101.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 0/168 major bleeding events in the inpatient group vs 2/171 major bleeding events in the outpatient group. No major bleeding occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b> </p> <p>Follow‐up: 90 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 6.88 (0.36 to 132.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 0/168 major bleeding events in the inpatient group vs 3/171 major bleeding events in the outpatient group. No major bleeding occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor bleeding</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 1.08 (0.07 to 16.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>106 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One participant in each treatment arm reported minor bleeding.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000 (1 to 305)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrent PE</b> </p> <p>Follow‐up: within 90 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 2.95 (CI 0.12 to 71.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 0/168 recurrent PE in inpatient group vs 1/171 recurrent PE in the outpatient group, within 90 days. No recurrent PE occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>PE</b>: pulmonary embolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Outpatients received subcutaneous enoxaparin twice daily (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>), or rivaroxaban 15 mg orally twice daily for the first 21 days, followed by 20 mg orally once daily for approximately 69 days, for a total treatment duration of 90 days (<a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>).<br/><sup>b</sup>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, the inpatient group was admitted to hospital and received subcutaneous enoxaparin 1 mg/kg twice daily. In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, the inpatient group was admitted to hospital and received variable pharmacotherapy (standard‐of‐care treatment).<br/><sup>c</sup>We downgraded by two levels as the small sample size means it is unlikely that rare events will be seen and because publication bias could not be discounted.<br/><sup>d</sup>We downgraded by two levels due to the overall small sample size, small number of events, imprecision in the confidence intervals and the fact that publication bias could not be discounted.<br/><sup>e</sup>Additional information was requested from the study authors, but as they were unable to provide it, we used only the available data. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010019-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010019-sec-0009"></div> <section id="CD010019-sec-0010"> <h3 class="title" id="CD010019-sec-0010">Description of the condition</h3> <p>Pulmonary embolism (PE) is a common life‐threatening cardiovascular illness. It is a potentially fatal disease that, despite adequate treatment, is still associated with high morbidity and mortality; the reported incidence in the USA exceeds one case per 1000 population, and in Europe, annual mortality is more than seven deaths per 100,000 population (<a href="./references#CD010019-bbs2-0014" title="BarcoS , MahmoudpourSH , ValerioL , KlokFA , MünzelT , MiddeldorpS , et al.Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respiratory Medicine2020;8(3):277-87.">Barco 2020</a>). <a href="./references#CD010019-bbs2-0028" title="HeitJA , CohenAT , AndersonFA .VTE Impact Assessment Study Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood2005;106(11):267a.">Heit 2005</a> estimated that there are around 237,000 cases of non‐fatal PE and 294,000 cases of fatal PE each year in the USA. <a href="./references#CD010019-bbs2-0019" title="CohenAT , AgnelliG , AndersonFA , ArcelusJI , BergqvistD , BrechtJG , et al.Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis2007;98(4):756-64.">Cohen 2007</a> reported that of all people admitted to hospitals, 1% die of acute PE, and about 10% of all in‐hospital deaths are PE‐related. In six European countries with a total population of 454.4 million, more than 370,000 deaths were related to venous thromboembolism (VTE) in 2004, as estimated using an epidemiological model (<a href="./references#CD010019-bbs2-0019" title="CohenAT , AgnelliG , AndersonFA , ArcelusJI , BergqvistD , BrechtJG , et al.Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis2007;98(4):756-64.">Cohen 2007</a>). </p> <p>The diagnosis of PE has improved with advances in imaging technology, and PE management has changed with the introduction of treatments such as non‐vitamin K antagonist oral anticoagulants (NOACs) since 2010. In 2011, Pollack and colleagues reported a 5.4% all‐cause mortality rate across 22 medical centres in the USA (<a href="./references#CD010019-bbs2-0054" title="PollackCV , SchreiberD , Goldhaber SZ, SlatteryD , FanikosJ , O'NeilBJ , et al.Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). Journal of the American College of Cardiology2011;57(6):700-6.">Pollack 2011</a>). However, with the progressive use of NOACS, mortality from PE has also changed. The international Computerized Registry of Patients with Venous Thromboembolism (RIETE registry) of over 23,000 patients, <a href="./references#CD010019-bbs2-0036" title="JiménezD , Miguel-DiezJ , GuijarroR , Trujillo-SantosJ , OteroR , BarbaR , et al.Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE registry. Journal of the American College of Cardiology2016;67(2):162-70.">Jiménez 2016</a> noted a 30‐day all‐cause mortality rate of 5.9%, while <a href="./references#CD010019-bbs2-0066" title="VinsonDR , MarkDG , ChettipallyUK , HuangJ , RauchwergerAS , ReedME , et al.Increasing safe outpatient management of emergency department patients with pulmonary embolism a controlled pragmatic trial. Annals of Internal Medicine2018;169(12):855-65.">Vinson 2018</a> found a 30‐day all‐cause mortality rate of 4.4% across 21 USA medical centres. </p> <p>The prognosis and treatment of people diagnosed with acute PE are related to initial haemodynamic status. High‐risk PE (massive PE) – defined by the presence of shock or persistent arterial hypotension (systolic blood pressure below 90 mmHg or systolic blood pressure drop by 40 mmHg or more, for over 15 minutes, if not caused by new‐onset arrhythmia, hypovolaemia, or sepsis) – accounts for 5% of all cases of PE and has a poor prognosis, with short‐term mortality of more than 15% (<a href="./references#CD010019-bbs2-0042" title="KonstantinidesS , TorbickiA , AgnelliG , DanchinN , FitzmauriceD , GalièN , et al.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal2014;35(43):3033–73. [DOI: 10.1093/eurheartj/ehu283]">Konstantinides 2014</a>). Conversely, in haemodynamically stable patients, low risk PE (non‐massive PE) accounts for 95% of all cases of PE and has significantly lower short‐term mortality, ranging from under 1% to 15% (<a href="./references#CD010019-bbs2-0018" title="BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al.Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. New England Journal of Medicine2003;349(18):1695-702.">Buller 2003</a>; <a href="./references#CD010019-bbs2-0032" title="IbrahimSA , StoneRA , ObroskyDS , GengM , FineMJ , AujeskyD .Thrombolytic therapy and mortality in patients with acute pulmonary embolism. Archives of Internal Medicine2008;168(20):2183-90.">Ibrahim 2008</a>; <a href="./references#CD010019-bbs2-0042" title="KonstantinidesS , TorbickiA , AgnelliG , DanchinN , FitzmauriceD , GalièN , et al.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal2014;35(43):3033–73. [DOI: 10.1093/eurheartj/ehu283]">Konstantinides 2014</a>; <a href="./references#CD010019-bbs2-0055" title="QuinlanDJ , McQuillanA , EikelboomJW .Low-molecular weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Annals of Internal Medicine2004;140(3):175-83.">Quinlan 2004</a>). The question is whether people with low‐risk PE should be treated as outpatients or inpatients. </p> </section> <section id="CD010019-sec-0011"> <h3 class="title" id="CD010019-sec-0011">Description of the intervention</h3> <p>The traditional initial anticoagulant therapy for acute PE in hospitals is standardised intravenous unfractionated heparin (UFH), subcutaneous low molecular weight heparins (LMWH), or fondaparinux, started together with oral vitamin K antagonists (referred as the overlap treatment period) for at least five days until the prothrombin time yields an international normalised ratio above 2.0 for two consecutive days. </p> <p>Since the 1990s, the practical advantages of LMWH over UFH have allowed outpatient treatment in patients with VTE in many situations without laboratory anticoagulant monitoring (<a href="./references#CD010019-bbs2-0051" title="OthienoR , OkpoE , ForsterR .Home versus in-patient treatment for deep vein thrombosis. Cochrane Database of Systematic Reviews2018, Issue 1. Art. No: CD003076. [DOI: 10.1002/14651858.CD003076.pub3]">Othieno 2018</a>). Although most people with acute PE are hospitalised during initial therapy, it is feasible that in selected low‐risk people, outpatient care can safely and effectively be used rather than inpatient care. </p> <p>The NOACs, including factor Xa inhibitors (e.g. rivaroxaban, apixaban, and edoxaban) and direct thrombin inhibitors (e.g. dabigatran), are available in many countries for treating VTE. In patients with PE who are haemodynamically stable (PE without hypotension), NOACs are efficient and safe (<a href="./references#CD010019-bbs2-0025" title="GhazvinianR , GottsäterA , ElfJL .Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism. Journal of Thrombosis and Thrombolysis2018;45:319–24.">Ghazvinian 2018</a>). The 10th edition of the American College of Chest Physicians (ACCP) guidelines suggests administering initial parenteral anticoagulation before dabigatran and edoxaban, while rivaroxaban and apixaban do not require initial parenteral anticoagulation (<a href="./references#CD010019-bbs2-0040" title="KearonC , AklEA , OrnelasJ , BlaivasA , JimenezD , BounameauxH , et al.Antithrombotic therapy for VTE disease and expert panel report (10th edition). Chest2016;149(2):315-52.">Kearon 2016</a>). </p> <p>Studies comparing inpatient versus outpatient treatment for PE have used early discharge as soon as patients achieve a clinically stable condition (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>; <a href="./references#CD010019-bbs2-0007" title="OteroR , UresandiF , JiménezD , CabezudoMA , OribeM , NauffalD , et al.Home treatment in pulmonary embolism. Thrombosis Research2010;126(1):e1-5. ">Otero 2010</a>). Outpatient treatment of a substantial number of patients with low‐risk acute PE (even during the traditional period of overlap with heparin and vitamin K antagonists) seems to be a feasible option. </p> </section> <section id="CD010019-sec-0012"> <h3 class="title" id="CD010019-sec-0012">How the intervention might work</h3> <p>Most cases of acute PE are managed within a hospital setting because of the uncertainty in determining whether patients are at high or low risk. In addition, during management of acute PE, some patients require intensive treatment in hospital due to potentially fatal complications such as clinical deterioration. Therefore, when considering management in an outpatient setting, it is important to identify patients who are considered at low risk of major (fatal) complications. In selected low‐risk patients, more than 98% of outpatients have an uncomplicated course (<a href="./references#CD010019-bbs2-0064" title="van derWallSJ , HendriksSV , HuismanMV , KlokFA .Home treatment of acute pulmonary embolism: state of the art in 2018. Current Opinion in Pulmonary Medicine2018;24(5):425-31.">Van der Wall 2018</a>). </p> <p>Several risk assessment strategies, such as clinical scores, imaging modalities, and laboratory biomarkers are available to identify patients who could potentially be treated safely as outpatients. <a href="./references#CD010019-bbs2-0009" title="AgterofMJ , SchutgensRE , SnijderRJ , EppingG , PeltenburgHG , PosthumaEF , et al.Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. Journal of Thrombosis and Haemostasis2010;8(6):1235-41.">Agterof 2010</a> reported that haemodynamically stable patients with low N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) levels (less than 500 pg/mL) would be a safe group of patients to receive care in an outpatient setting. Furthermore, <a href="./references#CD010019-bbs2-0045" title="LankeitM , JiménezD , KostrubiecM , DellasC , HasenfussG , PruszczykP , et al.Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation2011;124(24):2716-24.">Lankeit 2011</a> considered the troponin T (TnT) assay, along with the simplified Pulmonary Embolism Severity Index (sPESI), as a risk assessment tool to identify patients with acute PE who could be safely treated as outpatients. </p> <p>In addition, there are several scoring systems to select low‐risk patients with acute PE for outpatient management (<a href="./references#CD010019-bbs2-0033" title="Jara-PalomaresL , AlfonsoM , MaestreA , JimenezD , Garcia-BragadoF , FontC , et al.Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged &lt;50 years. Scientific Reports2019;9:20064. [DOI: 10.1038/s41598-019-55213-8]">Jara‐Palomares 2019</a>). The most widely used and validated scores include the Geneva prediction score (GPS), the Pulmonary Embolism Severity Index (PESI), the simplified version of the PESI (sPESI) and Hestia criteria (<a href="./references#CD010019-bbs2-0010" title="AujeskyD , ObroskyDS , StoneRA , AubleTE , PerrierA , CornuzJ , et al.Derivation and validation of a prognostic model for pulmonary embolism. American Journal of Respiratory and Critical Care Medicine2005;172(8):1041-6.">Aujesky 2005</a>; <a href="./references#CD010019-bbs2-0022" title="den ExterPL , ZondagW , KlokFA , BrouwerRE , DolsmaJ , EijsvogelM , et al.Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without N-terminal pro–brain natriuretic peptide testing in patients with acute pulmonary embolism. American Journal of Respiratory and Critical Care Medicine2016;194(8):998-1006.">Den Exter 2016b</a>; <a href="./references#CD010019-bbs2-0035" title="JimenezD , AujeskyD , MooresL , GomezV , LoboJL , et al.Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. Archieves of Internal Medicine2010;170(15):1383-9.">Jiménez 2010</a>; <a href="./references#CD010019-bbs2-0067" title="WickiJ , PerrierA , PernegerTV , BounameauxH , JunodAF .Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thrombosis and Haemostasis2000;84(4):548-52.">Wicki 2000</a>). </p> <p> <ul id="CD010019-list-0001"> <li> <p>The GPS was derived from 296 outpatients confirmed with symptomatic acute PE and identifies six independent predictors (cancer, heart failure, previous deep vein thrombosis (DVT), systolic blood pressure less than 100 mmHg, partial pressure of oxygen dissolved in arterial blood (PaO<sub>2</sub>) less than 8 kPa, and presence of DVT on ultrasound exam) of an adverse outcome (death, recurrent thromboembolic event or major bleeding) in a three‐month follow‐up period (<a href="./references#CD010019-bbs2-0067" title="WickiJ , PerrierA , PernegerTV , BounameauxH , JunodAF .Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thrombosis and Haemostasis2000;84(4):548-52.">Wicki 2000</a>, see <a href="./appendices#CD010019-sec-0089">Appendix 1</a>). </p> </li> <li> <p>The PESI criteria were derived from 15,531 inpatients discharged with PE and consists of 11 factors independently associated with 30‐day mortality: age, male sex, cancer, heart failure, chronic lung disease, pulse rate 110 beats/minutes or greater, systolic blood pressure less than 100 mmHg, respiratory rate 30 breaths/minute or greater, body temperature less than 36°C, altered mental status, and oxyhaemoglobin saturation less than 90% (<a href="./references#CD010019-bbs2-0010" title="AujeskyD , ObroskyDS , StoneRA , AubleTE , PerrierA , CornuzJ , et al.Derivation and validation of a prognostic model for pulmonary embolism. American Journal of Respiratory and Critical Care Medicine2005;172(8):1041-6.">Aujesky 2005</a>, see <a href="./appendices#CD010019-sec-0090">Appendix 2</a>). </p> </li> <li> <p>The sPESI was developed with six items that may be more useful and practical for routine use in emergency departments. This tool can predict 30‐day mortality after acute PE and has similar prognostic accuracy to the original PESI (<a href="./references#CD010019-bbs2-0035" title="JimenezD , AujeskyD , MooresL , GomezV , LoboJL , et al.Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. Archieves of Internal Medicine2010;170(15):1383-9.">Jiménez 2010</a>, see <a href="./appendices#CD010019-sec-0091">Appendix 3</a>). </p> </li> <li> <p>The Hestia criteria is specifically designed to identify patients who can be safely treated in an outpatient setting and therefore comprise only contraindications to outpatient treatment. The Hestia criteria were derived from a multicentre prospective cohort study in 297 patients treated as outpatients among 581 patients with PE (<a href="./references#CD010019-bbs2-0008" title="ZondagW , MosIC , Creemers-SchildD , HoogerbruggeAD , DekkersOM , DolsmaJ , et al.Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. Journal of Thrombosis and Haemostasis2011;9(8):1500-7. ">Zondag 2011</a>, see <a href="./appendices#CD010019-sec-0092">Appendix 4</a>). These criteria use 11 practical clinical exclusion rules to select patients for outpatient treatment. Later on, these criteria were validated in 550 patients by combining them with a cutoff of 500 ng/L for NT‐proBNP levels in outpatient treatment (<a href="./references#CD010019-bbs2-0022" title="den ExterPL , ZondagW , KlokFA , BrouwerRE , DolsmaJ , EijsvogelM , et al.Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without N-terminal pro–brain natriuretic peptide testing in patients with acute pulmonary embolism. American Journal of Respiratory and Critical Care Medicine2016;194(8):998-1006.">Den Exter 2016b</a>). </p> </li> </ul> </p> <p><a href="./references#CD010019-bbs2-0034" title="JiménezD , YusenRD , OteroR , UresandiF , NauffalD , LasernaE , et al.Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest2007;132(1):24-30.">Jiménez 2007</a> compared two models (GPS and PESI) using a distinct set of ambulatory patients with acute symptomatic PE to identify low‐risk patients for anticoagulant therapy in the outpatient setting. In this study, the PESI quantified the prognosis of patients with acute PE significantly better than the GPS. Hence, the PESI can very accurately select and identify low‐risk patients for adverse events within 30 days of anticoagulant therapy in acute PE. </p> <p><a href="./references#CD010019-bbs2-0069" title="ZondagW , den ExterPL , CrobachMJT , DolsmaA , DonkerML , et al.Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism. Thrombosis and Haemostasis2013;109:47-52.">Zondag 2013</a> compared the performance of the sPESI versus the Hestia criteria for selecting low‐risk patients for anticoagulant therapy in the outpatient setting. This study demonstrated that both the sPESI and the Hestia criteria classified different patients as being suitable for outpatient treatment, suggesting that when the Hestia criteria are applied, they may identify a proportion of patients considered as high risk by sPESI (such as those with malignant diseases, cardiopulmonary comorbidities, or advanced age) to be treated as outpatients. </p> <p>In a recent direct comparison, the Hestia and sPESI criteria were shown to be equally safe and effective, identifying more than a third of patients with acute PE for outpatient treatment with favourable outcomes (<a href="./references#CD010019-bbs2-0058" title="RoyPM , PenalozaA , HugliO , KlokFA , ArnouxA , EliasA , et al.Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. European Heart Journal2021;42(33):3146-57.">Roy 2021</a>). Haemodynamically stable patients with a PESI score I or II, or negative by the Hestia criteria and who have adequate home support, are eligible for early discharge or outpatient treatment (<a href="./references#CD010019-bbs2-0015" title="BarraSN , PaivaL , ProvidênciaR , FernandesA , MarquesAL .A review on state-of-the-art data regarding safe early discharge following admission for pulmonary embolism: what do we know?Clinical Cardiology2013;36(9):507-15.">Barra 2013</a>; <a href="./references#CD010019-bbs2-0053" title="PiranS , Le GalG , WellsPS , GandaraE , RighiniM , RodgerMA , et al.Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. Thrombosis Research2013;132(5):515-9.">Piran 2013</a>). </p> </section> <section id="CD010019-sec-0013"> <h3 class="title" id="CD010019-sec-0013">Why it is important to do this review</h3> <p>The eighth edition of the ACCP guidelines discussed the feasibility of outpatient treatment in acute PE among a substantial proportion of patients, but they provided no formal recommendations (<a href="./references#CD010019-bbs2-0038" title="KearonC , KahnSR , AgnelliG , GoldhaberS , RaskobGE , ComerotaAJ , American College of Chest Physicians.Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest2008;133(6 Suppl):454S-545S.">Kearon 2008</a>). In the same way, the task force of the European Society of Cardiology did not clearly recommend early discharge or outpatient management for acute PE in selected patients (<a href="./references#CD010019-bbs2-0042" title="KonstantinidesS , TorbickiA , AgnelliG , DanchinN , FitzmauriceD , GalièN , et al.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal2014;35(43):3033–73. [DOI: 10.1093/eurheartj/ehu283]">Konstantinides 2014</a>). The ninth edition of the ACCP guidelines suggested early discharge over standard discharge (e.g. after the first five days of treatment) for patients with low‐risk PE whose home circumstances were adequate (Grade 2B) (<a href="./references#CD010019-bbs2-0039" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al.Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guideline. Chest2012;141(2 Suppl):e419S-94S.">Kearon 2012</a>). However, patients who preferred the security of the hospital to the convenience and comforts of home were likely to choose hospitalisation over outpatient treatment. </p> <p>The increasing availability of NOACs for treating acute PE allows management without the need for hospitalisation. Hence, the 10th edition of the ACCP guidelines suggested outpatient treatment for acute PE, provided that patients fulfil the following conditions. </p> <p> <ul id="CD010019-list-0002"> <li> <p>Clinically stable with good cardiopulmonary reserve.</p> </li> <li> <p>No contraindications such as recent haemorrhage, severe kidney or liver disease, or severe thrombocytopenia (i.e. platelets less than 70,000/mm<sup>3</sup>). </p> </li> <li> <p>Expected to adhere to treatment.</p> </li> <li> <p>The patient feels confident to be treated at home.</p> </li> </ul> </p> <p>However, in patients with right ventricular dysfunction or increased cardiac biomarker levels, out‐of‐hospital treatment is not recommended (<a href="./references#CD010019-bbs2-0040" title="KearonC , AklEA , OrnelasJ , BlaivasA , JimenezD , BounameauxH , et al.Antithrombotic therapy for VTE disease and expert panel report (10th edition). Chest2016;149(2):315-52.">Kearon 2016</a>). </p> <p>The 2018 guideline from the British Thoracic Society proposes similar recommendations (<a href="./references#CD010019-bbs2-0031" title="HowardLS , BardenS , CondliffeR , ConnollyV , DaviesCW , DonaldsonJ , et al.British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax2018;73:ii1-ii29. doi:10.1136/thoraxjnl-2018-211539.">Howard 2018</a>). Patients with confirmed PE should be risk‐stratified using a validated clinical risk score: patients in PESI class I/II, sPESI class 0, or those meeting the Hestia criteria should be considered for outpatient management of PE. Where PESI or sPESI is used and indicates a low risk, physicians should consider a set of exclusion criteria for the outpatient management of PE (<a href="./appendices#CD010019-sec-0093">Appendix 5</a>). Recent NICE recommendations consider outpatient treatment for people with low‐risk PE and stress the importance of using a validated severity score to identify candidates while taking into account individual circumstances (<a href="./references#CD010019-bbs2-0050" title="National Institute for Health and Care Excellence (NICE).Venous thromboembolic diseases: diagnosis, management and thrombophilia testing NG158. nice.org.uk/guidance/ng158 (accessed 16 February 2022).">NICE 2020</a>). </p> <p>Outpatient treatment instead of traditional inpatient treatment in selected low‐risk patients with acute PE can provide several advantages, for example, a reduction in the number of hospitalisations, substantial cost savings, and an improvement in health‐related quality of life (<a href="./references#CD010019-bbs2-0020" title="DastaJF , PilonD , ModySH , LopattoK , LalibertéG , GermainG , et al.Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. Thrombosis Research2015;135(2):303-10.">Dasta 2015</a>; <a href="./references#CD010019-bbs2-0024" title="FanikosJ , RaoA , SegerAC , CarterD , PiazzaG , GoldhaberSZ .Hospital costs of acute pulmonary embolism. American Journal of Medicine2013;126(2):127-32.">Fanikos 2013</a>). This is an update of an earlier Cochrane Review and aims to present evidence to help guide decision‐making on whether outpatient treatment is as safe and effective as inpatient treatment for acute PE in clinically stable, low‐risk patients. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010019-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010019-sec-0014"></div> <p>To assess the effects of outpatient versus inpatient treatment in low‐risk patients with acute PE. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010019-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010019-sec-0015"></div> <section id="CD010019-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010019-sec-0017"> <h4 class="title">Types of studies</h4> <p>This systematic review included randomised controlled trials (RCTs) as well as quasi‐RCTs (in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods), as we did not anticipate finding many RCTs in this area. </p> </section> <section id="CD010019-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults (18 years and older) diagnosed with low‐risk acute pulmonary embolism (PE), defined as acute onset of dyspnoea or chest pain together with a new contrast‐filling defect on single‐ or multi‐detector computed tomography (CT) pulmonary angiography or pulmonary digital angiography, a new high‐probability ventilation‐perfusion lung scan or documentation of a new proximal deep vein thrombosis (DVT) either by venous ultrasonography or contrast venography. </p> <p>We considered people to be at low risk if they were classified as such by any validated or non‐validated measurement tool that aimed to classify mortality risk rate related to PE, such as the Geneva prediction score (GPS), the Pulmonary Embolism Severity Index (PESI), the simplified PESI (sPESI), or the Hestia criteria. </p> </section> <section id="CD010019-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD010019-list-0003"> <li> <p>Intervention group: participants allocated to outpatient management for acute PE.</p> </li> <li> <p>Control group: participants allocated to hospital (inpatient) management for acute PE. </p> </li> </ul> </p> <p>We considered outpatients as people who were discharged within 36 hours after the low‐risk acute PE diagnosis and who then completed treatment as outpatients. </p> </section> <section id="CD010019-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD010019-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010019-list-0004"> <li> <p>Short‐term all‐cause mortality (from the date of randomisation to 10 and to 30 days).</p> </li> <li> <p>Long‐term all‐cause mortality (from the date of randomisation to 90 days).</p> </li> </ul> </p> <p>Long‐term all‐cause mortality at 90 days included any all‐cause mortality noted from the date of randomisation to 90 days. We considered both all‐cause mortality and PE‐related mortality. </p> </section> <section id="CD010019-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010019-list-0005"> <li> <p>Bleeding (from the date of randomisation to 90 days): we defined major bleeding as fatal or clinically overt bleeding resulting in fall of haemoglobin by 2 g/L or more, or bleeding into critical anatomical sites (subdural haematoma, intraspinal haemorrhage, retroperitoneal, intraocular, pericardial, atraumatic intra‐articular), or leading to transfusion of 2 U or more of blood or red cells (<a href="./references#CD010019-bbs2-0059" title="SchulmanS , KearonC .Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>). We defined minor bleeding as bleeding requiring intervention but not qualifying as a major bleeding, including bleeding precipitating treatment cessation (<a href="./references#CD010019-bbs2-0059" title="SchulmanS , KearonC .Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>). </p> </li> <li> <p>Adverse effects, such as haemodynamic instability (from the date of randomisation to 90 days). </p> </li> <li> <p>Recurrence of PE (from the date of randomisation to 90 days).</p> </li> <li> <p>Patient satisfaction, adherence, or both (from the date of randomisation to 90 days): we accepted methods used by study investigators, including Likert scale questionnaires. </p> </li> </ul> </p> </section> </section> </section> <section id="CD010019-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010019-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for RCTs and controlled clinical trials, with no restrictions on language, publication year, or publication status. </p> <p> <ul id="CD010019-list-0006"> <li> <p>The Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web, searched on 31 May 2021). </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Register of Studies Online (2021, Issue 4). </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE; searched from 26 March 2018 to 31 May 2021). </p> </li> <li> <p>Embase Ovid (searched from 26 March 2018 to 31 May 2021).</p> </li> <li> <p>CINAHL Ebsco (searched from 26 March 2018 to 31 May 2021).</p> </li> <li> <p>AMED Ovid (searched from 26 March 2018 to 31 May 2021).</p> </li> </ul> </p> <p>The Information Specialist modelled search strategies for other databases on the search strategy designed for CENTRAL. Where appropriate, these were combined with adaptations of the highly sensitive search strategy designed by Cochrane for identifying RCTs and controlled clinical trials (as described in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i><a href="./references#CD010019-bbs2-0047" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , MetzendorfMI , et al.Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2021</a>). Search strategies for major databases are provided in <a href="./appendices#CD010019-sec-0094">Appendix 6</a>. </p> <p>The Information Specialist searched the following trial registries on 31 May 2021.</p> <p> <ul id="CD010019-list-0007"> <li> <p>The World Health Organization International Clinical Trials Registry Platform (<a href="http://who.int/trialsearch" target="_blank">who.int/trialsearch</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> </section> <section id="CD010019-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of the identified studies for additional citations.</p> </section> </section> <section id="CD010019-sec-0026"> <h3 class="title" id="CD010019-sec-0026">Data collection and analysis</h3> <section id="CD010019-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HHBY, VSNN) independently screened the trials identified by the literature search by title and abstract. Two of a possible four review authors assessed the full text of potentially relevant reports (HHBY, VSNN, PVB, CB). We resolved disagreements by discussion (PJFVB). </p> </section> <section id="CD010019-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HHBY, VSNN) independently extracted data, resolving any discrepancies by discussion. We used a standard data extraction form to extract the following information: characteristics of the study (design, randomisation methods), participants, interventions, and outcomes (types of outcome measures, adverse events); and details on study funding and study authors' declarations of interest. We then checked for accuracy before entering the data in Review Manager 5 software (<a href="./references#CD010019-bbs2-0056" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD010019-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed methodological quality using Cochrane's 'Risk of bias' tool (<a href="./references#CD010019-bbs2-0029" title="HigginsJP , AltmanDG , SterneJAC .Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We used the following six criteria. </p> <section id="CD010019-sec-0030"> <h5 class="title">Random sequence generation</h5> <p>We considered random sequence generation to be at low risk of bias where the method used was either adequate or unlikely to introduce bias; at unclear risk where there was insufficient information to assess whether the method used was likely to introduce bias; or at high risk when the method used (e.g. quasi‐randomised trials) was improper and likely to introduce bias. </p> </section> <section id="CD010019-sec-0031"> <h5 class="title">Allocation concealment</h5> <p>We recorded allocation concealment as being at low risk of bias when the method used (e.g. central allocation) was unlikely to introduce bias in the final observed effect; at unclear risk when there was insufficient information to assess whether the method used was likely to introduce bias in the estimate of effect; or at high risk when the method used (e.g. open random allocation schedule) was likely to introduce bias in the final observed effect. </p> </section> <section id="CD010019-sec-0032"> <h5 class="title">Blinding</h5> <p>For this clinical review, it is not possible to blind participants and investigators to treatment allocation (i.e. inpatient and outpatient), so we did not consider performance bias as part of the risk of bias assessment. We did consider blinding of outcome measures and recorded blinding of assessors as being at low risk of bias if blinding was performed adequately, or the outcome measurement was not likely to be influenced by lack of blinding; at unclear risk if there was insufficient information to assess whether the type of blinding used was likely to introduce bias in the estimate of effect; or at high risk if there was no blinding or incomplete blinding, and the outcome or the outcome measurement was likely to be influenced by lack of blinding. </p> </section> <section id="CD010019-sec-0033"> <h5 class="title">Incomplete outcome data</h5> <p>We recorded incomplete outcome data as being at low risk of bias when the underlying reasons for missing data were unlikely to make treatment effects depart from plausible values, or proper methods were employed to handle missing data. In addition, we considered a withdrawal rate less than 20% in each group to be low risk. We recorded an unclear risk of bias when there was insufficient information to assess whether the missing data mechanism, in combination with the method used to handle missing data, was likely to introduce bias in the estimate of effect; and a high risk of bias when the crude estimate of effects (e.g. complete‐case estimate) was clearly biased due to the underlying reasons for missing data, and the methods used to handle missing data were unsatisfactory. </p> </section> <section id="CD010019-sec-0034"> <h5 class="title">Selective reporting</h5> <p>We recorded selective reporting as being at low risk of bias when the trial protocol was available and all of the trial's prespecified outcomes that were of interest in the review were reported. We recorded an unclear risk of bias when there was insufficient information to assess whether the magnitude and direction of the observed effect was related to selective outcome reporting; or as being at high risk when not all of the trial's prespecified primary outcomes were reported. </p> </section> <section id="CD010019-sec-0035"> <h5 class="title">Other bias</h5> <p>We considered aspects of methodology that might have been influenced by vested interests and which may have led directly to a risk of bias as 'other bias'. </p> <p>Two review authors (VSNN, PJFVB) independently made a judgement as to whether the risk of bias for each criterion was low, unclear, or high. We resolved disagreements by discussion. We considered trials that were classified as being at low risk of bias in sequence generation, allocation concealment, blinding of outcome assessors, incomplete data, and selective outcome reporting as trials that were at overall low risk of bias. </p> </section> </section> <section id="CD010019-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010019-sec-0037"> <h5 class="title">Binary outcomes</h5> <p>We used risk ratios (RRs) as the effect measure with 95% confidence intervals (CIs) for dichotomous data. </p> </section> <section id="CD010019-sec-0038"> <h5 class="title">Continuous outcomes</h5> <p>We planned to present the results as mean differences (MDs) with 95% CIs for continuous data. When pooling data across studies, we planned to use MDs if the outcomes were measured in the same way between trials. We planned to use standardised mean differences to combine trials that measured the same outcome but used different methods. </p> </section> </section> <section id="CD010019-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was each participant recruited into each study.</p> </section> <section id="CD010019-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>In an intention‐to‐treat (ITT) analysis, all the participants in a trial are analysed according to the intervention to which they were allocated, whether they received the intervention or not. For each trial, we reported whether or not the investigators stated if the analysis was performed according to the ITT principle. If participants were excluded after allocation, we reported any details provided in full. Furthermore, we performed the analysis on an ITT basis whenever possible (<a href="./references#CD010019-bbs2-0049" title="NewellDJ .Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology1992;21(5):837-41.">Newell 1992</a>). Otherwise, we adopted the 'available‐case analysis'. Study authors provided some further information on missing data when requested (<a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>). When this was not possible, we used only available data in the analyses. </p> </section> <section id="CD010019-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We looked for clinical heterogeneity by examining the study details and then tested for statistical heterogeneity between trial results using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic (<a href="./references#CD010019-bbs2-0021" title="DeeksJJ , HigginsJP , Altman DG (editors).Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2/chapter-10.">Deeks 2011</a>). We are aware that thresholds for interpretation of I<sup>2</sup> can be misleading in that the importance of inconsistency depends on several factors. We considered size and direction of effect and interpreted heterogeneity using the following I<sup>2</sup> thresholds for interpretation as described in the <i>Cochrane Handbook</i> (<a href="./references#CD010019-bbs2-0030" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). </p> <p> <ul id="CD010019-list-0008"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: might represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: might represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD010019-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess the likelihood of potential publication bias using funnel plots in addition to assessing the risk of selective outcome reporting, considered under the risk of bias assessment for included studies. When small studies in a meta‐analysis tend to show larger treatment effects, we planned to consider other causes including selection biases, poor methodological quality, heterogeneity, and chance. However, the number of studies included in the review prevented this. </p> </section> <section id="CD010019-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We used the fixed‐effect model to analyse data. If we identified substantial heterogeneity (e.g. I<sup>2</sup> greater 50%), we planned to compute pooled estimates of the treatment effect for each outcome using a random‐effects model (with two or more studies). We undertook quantitative analysis of outcomes on an ITT basis. </p> </section> <section id="CD010019-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the case of substantial clinical heterogeneity (I<sup>2</sup> greater than 50%), we planned to use subgroup analysis to explore the results. We planned to perform the Chi<sup>2</sup> test for subgroup differences, set at a P value of 0.05. We planned to carry out analysis of the following subgroups when sufficient data were available. </p> <p> <ul id="CD010019-list-0009"> <li> <p>LMWH (e.g. tinzaparin, enoxaparin, dalteparin) and selective factor Xa inhibitors (e.g. fondaparinux). </p> </li> <li> <p>Once‐daily versus twice‐daily administration of LMWH and selective factor Xa inhibitors.</p> </li> <li> <p>Outpatient discharge period (24 hours or less versus more than 24 hours).</p> </li> <li> <p>Classification criteria (i.e. PESI versus GPS).</p> </li> <li> <p>Inpatients and outpatients with the same versus different treatment regimens.</p> </li> </ul> </p> </section> <section id="CD010019-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>If sufficient numbers of studies were identified for inclusion, we planned to perform a sensitivity analysis to explore causes of heterogeneity and the robustness of the results. We planned to include the following factors in the sensitivity analysis, separating studies according to: </p> <p> <ul id="CD010019-list-0010"> <li> <p>trials at low versus high risk of bias; and</p> </li> <li> <p>rates of withdrawal for each outcome (less than 20% versus 20% or greater).</p> </li> </ul> </p> <p>As only two studies were included we were unable to do this.</p> </section> <section id="CD010019-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table to present the main results of this review using GRADEpro GDT software (<a href="./references#CD010019-bbs2-0026" title="GRADEpro GDT.Version accessed 1 November 2018. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). We used the principles of the GRADE system to assess the certainty of the body of evidence associated with specific primary outcomes (short‐ and long‐term all‐cause mortality), as well as secondary outcomes (bleeding and recurrent PE) that were most clinically relevant to healthcare professionals and patients (<a href="./references#CD010019-bbs2-0027" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck-YtterY , SchunemannHJ .What is "quality of evidence" and why is it important to clinicians?BMJ2008;336:995-8.'>Guyatt 2008</a>). The GRADE approach appraises the certainty of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The assessment of the certainty of a body of evidence considers within‐study risk of bias (methodological quality), the directness of the evidence, heterogeneity of the data, precision of effect estimates, and risk of publication bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010019-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010019-sec-0047"></div> <section id="CD010019-sec-0048"> <h3 class="title">Description of studies</h3> <p>See <a href="#CD010019-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010019-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010019-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD010019-sec-0049"> <h4 class="title">Results of the search</h4> <p>For this update, database searches yielded a total of 8774 records. We used Cochrane's Screen4Me workflow to help identify potential reports of RCTs from the database search records. Results of the Screen4Me assessment process are shown in <a href="#CD010019-fig-0002">Figure 2</a>. We then assessed the remaining 4407 'possible' records identified by Screen4Me using Covidence (<a href="http://covidence.org/" target="_blank">covidence.org</a>). We did not identify any new studies for inclusion. We assessed one new study as excluded (<a href="./references#CD010019-bbs2-0006" title="MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al.Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. [DOI: 10.1160/TH17-05-0523]">Medina 2017</a>). See <a href="#CD010019-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010019-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Screen4Me flow diagram" data-id="CD010019-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Screen4Me flow diagram</p> </div> </div> </div> </section> <section id="CD010019-sec-0050"> <h4 class="title">Included studies</h4> <p>We included two studies involving a total of 453 participants that met the inclusion criteria (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>; <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>). <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> randomised 339 participants and <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> randomised 114 participants. See <a href="./references#CD010019-sec-0112" title="">Characteristics of included studies</a>. </p> <section id="CD010019-sec-0051"> <h5 class="title">Study design</h5> <p>Authors described both trials as international, open‐label, randomised, non‐inferiority trials (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>; <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>). They evaluated a period of three months. The studies differed both in terms of site of care and pharmacotherapy. </p> </section> <section id="CD010019-sec-0052"> <h5 class="title">Types of interventions</h5> <p><a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> compared outpatient treatment (171 participants) versus inpatient treatment (168 participants) for acute PE. </p> <p>Participants assigned to outpatient treatment received subcutaneous enoxaparin 1 mg/kg twice daily and were to be discharged from the emergency department (ED) within 24 hours of randomisation. If self‐injection was not possible, a study nurse either taught a caregiver to inject the enoxaparin or arranged administration by a visiting nurse. Participants assigned to receive inpatient treatment were admitted to hospital and received the same enoxaparin regimen. All participants received vitamin K antagonist therapy. </p> <p>In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, the outpatient group (51 participants) was discharged home from the ED no later than 24 hours after triage. They received 15 mg oral rivaroxaban twice daily for the first 21 days, followed by 20 mg oral rivaroxaban once daily for approximately 69 days, for a total treatment duration of 90 days. The inpatient comparison group (63 participants) received usual care according to local standard of care protocol and as defined by the medical team caring for the participant, which typically involved intravenous UFH or subcutaneous LMWH and hospitalisation but also included any of the NOACs. About three‐quarters of all participants were initially treated with unfractionated or LMWH but ultimately received NOACs, most commonly rivaroxaban (51%) or apixaban (25%). </p> </section> <section id="CD010019-sec-0053"> <h5 class="title">Types of outcomes measured</h5> <p><a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> considered the primary outcome of 'recurrence of symptomatic venous thromboembolism', as determined by helical CT or new perfusion defect involving 75% or more of a lung segment by lung scan; or pulmonary angiography; or autopsy; or documentation of a new proximal DVT either by venous ultrasonography or contrast venography (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>). </p> <p>As a safety measurement, the study assessed bleeding (evaluated at 14 and 90 days) and death. <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> defined major bleeding as fatal bleeding, bleeding at critical sites (i.e. intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular, pericardial or intramuscular with compartment syndrome), bleeding with a reduction of haemoglobin of 20 g/L or more, or resulting in transfusion of two units or more of packed red cells. </p> <p><a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> also assessed overall satisfaction 14 days after randomisation using a non‐validated five‐point Likert scale questionnaire. </p> <p><a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> evaluated the primary outcomes of duration of initial and subsequent hospitalisations for bleeding or VTE events (or both) within 30 days and 90 days of randomisation. The secondary outcomes of interest were percentage of participants with recurrence of symptomatic venous thromboembolism event (VTE), VTE‐related death (at 7, 14, 30, and 90 days), all‐cause mortality, serious adverse events, percentage of participants with the number of unplanned visits to the hospital or physician office for VTE symptoms or bleeding (at 7, 14, 30 and 90 days), minor bleeding, and mean combined duration of initial and subsequent ED hospitalisation for any reason up to 30 and 90 days. Patient satisfaction was evaluated at day 7 by means of five‐point and three‐point Likert scales, with higher scores indicating greater satisfaction. Satisfaction was further evaluated on day 90 with the Anti‐Clot Treatment Score, which uses two subscales of burdens (12 items) and benefits (3 items), both measured on a five‐point Likert scale, with higher scores indicating greater satisfaction. </p> </section> </section> <section id="CD010019-sec-0054"> <h4 class="title">Excluded studies</h4> <p>We excluded one new study for this update (<a href="./references#CD010019-bbs2-0006" title="MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al.Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. [DOI: 10.1160/TH17-05-0523]">Medina 2017</a>), bringing the total number of excluded studies to six (<a href="./references#CD010019-bbs2-0003" title="Den ExterPL , ZondagW , KlokFA , BrouwerRE , DolsmaJ , EijsvogelM , et al.Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without N-terminal pro–brain natriuretic peptide testing in patients with acute pulmonary embolism. American Journal of Respiratory and Critical Care Medicine2016;194(8):998-1006. ">Den Exter 2016a</a>; <a href="./references#CD010019-bbs2-0004" title="RoyPM , GableB .Hospitalization or Out-treatment ManagEment of Patients with Pulmonary Embolism: a randomized controlled trial (HOME-PE). clinicaltrials.gov/ct2/show/NCT02811237 (first received 23 June 2016). ">HOME Study</a>; <a href="./references#CD010019-bbs2-0005" title="KovacsMJ , RodgerM , AndersonDR , MorrowB , KellsG , KovacsJ , et al.Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Annals of Internal Medicine2003;138(9):714-9. ">Kovacs 2003</a>; <a href="./references#CD010019-bbs2-0006" title="MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al.Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. [DOI: 10.1160/TH17-05-0523]">Medina 2017</a>; <a href="./references#CD010019-bbs2-0007" title="OteroR , UresandiF , JiménezD , CabezudoMA , OribeM , NauffalD , et al.Home treatment in pulmonary embolism. Thrombosis Research2010;126(1):e1-5. ">Otero 2010</a>; <a href="./references#CD010019-bbs2-0008" title="ZondagW , MosIC , Creemers-SchildD , HoogerbruggeAD , DekkersOM , DolsmaJ , et al.Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. Journal of Thrombosis and Haemostasis2011;9(8):1500-7. ">Zondag 2011</a>). <a href="./references#CD010019-bbs2-0005" title="KovacsMJ , RodgerM , AndersonDR , MorrowB , KellsG , KovacsJ , et al.Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Annals of Internal Medicine2003;138(9):714-9. ">Kovacs 2003</a> was a randomised controlled clinical trial that evaluated different doses of warfarin in outpatients; <a href="./references#CD010019-bbs2-0008" title="ZondagW , MosIC , Creemers-SchildD , HoogerbruggeAD , DekkersOM , DolsmaJ , et al.Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. Journal of Thrombosis and Haemostasis2011;9(8):1500-7. ">Zondag 2011</a> was classified as cohort study; <a href="./references#CD010019-bbs2-0007" title="OteroR , UresandiF , JiménezD , CabezudoMA , OribeM , NauffalD , et al.Home treatment in pulmonary embolism. Thrombosis Research2010;126(1):e1-5. ">Otero 2010</a> considered early discharge to be at three to five days from admission, and <a href="./references#CD010019-bbs2-0003" title="Den ExterPL , ZondagW , KlokFA , BrouwerRE , DolsmaJ , EijsvogelM , et al.Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without N-terminal pro–brain natriuretic peptide testing in patients with acute pulmonary embolism. American Journal of Respiratory and Critical Care Medicine2016;194(8):998-1006. ">Den Exter 2016a</a> randomised participants to either outpatient treatment or to management according to N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) levels. We also excluded <a href="./references#CD010019-bbs2-0004" title="RoyPM , GableB .Hospitalization or Out-treatment ManagEment of Patients with Pulmonary Embolism: a randomized controlled trial (HOME-PE). clinicaltrials.gov/ct2/show/NCT02811237 (first received 23 June 2016). ">HOME Study</a>, which randomised participants to either Hestia or PESI management. <a href="./references#CD010019-bbs2-0006" title="MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al.Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. [DOI: 10.1160/TH17-05-0523]">Medina 2017</a> did not randomise participants to either outpatient or inpatient treatment. See <a href="./references#CD010019-sec-0113" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD010019-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010019-fig-0003">Figure 3</a> and <a href="#CD010019-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD010019-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD010019-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010019-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD010019-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD010019-sec-0056"> <h4 class="title">Allocation</h4> <p>We classified <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> as being at low risk of selection bias, as it used a computer programme to generate the allocation to treatment groups in a 1:1 ratio, with a randomised block design. We also classified <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> as being at low risk of selection bias because participants were randomly assigned in a 1:1 ratio to discharge or standard care by an interactive web system within 12 hours of diagnosis. </p> </section> <section id="CD010019-sec-0057"> <h4 class="title">Blinding</h4> <p>Since it is not possible to blind participants and investigators to treatment allocation for this particular clinical question, we did not consider performance bias as part of the risk of bias assessment. </p> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, data analysts were unmasked to treatment group assignment. However, there was a committee unaware of treatment assignment that confirmed all outcomes and classified all deaths as caused (or not) by PE, major bleeding, or another reason. Therefore, we judged the study to be at low risk of detection bias. </p> <p>In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, analysts were masked to treatment group assignment, and so we considered the study to be at low risk of bias. </p> </section> <section id="CD010019-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>Both studies reported less than 20% of dropouts and withdrawals – two from the outpatient group and five from the inpatient group in <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, and seven from the outpatient group and eight from the inpatient group in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. We classified both as being at unclear risk of attrition bias. In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, despite seven dropouts in the early‐discharge group, the study authors could confirm that all of these participants were alive at the end of the study. However, for the inpatient group they could not confirm whether two participants survived. In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, the study authors were unable to confirm how many of the individuals who did not complete the study survived. </p> </section> <section id="CD010019-sec-0059"> <h4 class="title">Selective reporting</h4> <p>There was no evidence of selective reporting in either of the included studies (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>; <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>). </p> </section> <section id="CD010019-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>There was no evidence of other potential sources of bias in the included studies (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>; <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>). We considered the imbalance between the two groups in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, as the arms received different pharmacotherapy regimens. However, as 50% of the outpatient group received the same treatment as the inpatient group, we judged both studies as being at low risk of other bias. </p> </section> </section> <section id="CD010019-sec-0061"> <h3 class="title" id="CD010019-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD010019-tbl-0001"><b>Summary of findings 1</b> Outpatient versus inpatient treatment for acute pulmonary embolism</a> </p> <section id="CD010019-sec-0062"> <h4 class="title">Outpatient versus inpatient treatment for acute pulmonary embolism</h4> <p>We identified two trials comparing outpatient (222 participants) versus inpatient (231 participants) treatment for acute PE (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>; <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>). The studies differed both in terms of site of care and pharmacotherapy. In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, both groups of participants received subcutaneous enoxaparin 1 mg/kg twice every day. In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, the outpatient group received rivaroxaban, and the inpatient group received standard care (treatment based on local institutional protocols, defined by the medical team caring for the participant, which typically involved bridging therapy and hospitalisation but also any of the NOACs). More than 75% of inpatients ultimately received some type of direct‐acting oral anticoagulant, with 50.8% receiving rivaroxaban. To investigate if the difference in treatment regimens influenced the results, we pooled the data from the studies using subgroup analysis. </p> <section id="CD010019-sec-0063"> <h5 class="title">Primary outcomes</h5> <section id="CD010019-sec-0064"> <h6 class="title">Short‐term all‐cause mortality (from the date of randomisation to 10 days)</h6> <p>No deaths occurred in either study within 10 days of randomisation (low‐certainty evidence). </p> </section> <section id="CD010019-sec-0065"> <h6 class="title">Short‐term all‐cause mortality (from the date of randomisation to 30 days)</h6> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, one death occurred on day 17 in the inpatient group (1/168), due to pneumonia and cancer, and there were no deaths in the outpatient group (0/171). No deaths occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. There was no clear effect of intervention due to this imprecision (risk ratio (RR) 0.33, 95% confidence interval (CI) 0.01 to 7.98; P = 0.49; 2 studies, 453 participants; low‐certainty evidence; <a href="./references#CD010019-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD010019-sec-0066"> <h6 class="title">Long‐term all‐cause mortality (from the date of randomisation to 90 days)</h6> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, one death occurred on day 17 in the inpatient group (1/168), due to pneumonia and cancer, and one death occurred on day 34 in the outpatient group (1/171), due to trauma‐related aortic rupture. No deaths occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. There was no clear effect of intervention due to imprecision (RR 0.98, 95% CI 0.06 to 15.58; P = 0.99; 2 studies, 451 participants; low‐certainty evidence; <a href="./references#CD010019-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD010019-sec-0067"> <h6 class="title">Short‐term pulmonary embolism‐related mortality (from the date of randomisation to 10 days) </h6> <p><a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> and <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> reported no short‐term PE‐related deaths. </p> </section> <section id="CD010019-sec-0068"> <h6 class="title">Long‐term pulmonary embolism‐related mortality (from the date of randomisation to 90 days) </h6> <p><a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> and <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> reported no long‐term PE‐related deaths. </p> </section> </section> <section id="CD010019-sec-0069"> <h5 class="title">Secondary outcomes</h5> <section id="CD010019-sec-0070"> <h6 class="title">Bleeding</h6> <section id="CD010019-sec-0071"> <p><b>Major bleeding</b></p> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, two outpatients (2/171) and no inpatients (0/168) had major bleeding within 14 days (one of the events was an intramuscular haematoma on day 3 and one was by insertion of vena cava filter on day 13). <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> reported no major bleeding by 90 days; we therefore assumed that no major bleeding had occurred by 14 days. There was no clear effect of intervention within 14 days due to this imprecision (RR 4.91, 95% CI 0.24 to 101.57; P = 0.30; 2 studies, 445 participants; low‐certainty evidence; <a href="./references#CD010019-fig-0007" title="">Analysis 1.3</a>). </p> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, three outpatients (3/171) and no inpatients (0/168) had major bleeding within 90 days. No major bleeding occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. There was no clear effect of intervention within 90 days due to imprecision (RR 6.88, 95% CI 0.36 to 132.14; P = 0.20; 2 studies, 445 participants; low‐certainty evidence; <a href="./references#CD010019-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD010019-sec-0072"> <p><b>Minor bleeding</b></p> <p><a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> did not report on minor bleeding. In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, two participants reported clinically relevant non‐major bleeding (as defined by the International Society on Thrombosis and Haemostasis), one from each randomisation group, which we considered as being minor bleeding. There was no clear effect of intervention due to imprecision (RR 1.08, 95% CI 0.07 to 16.79; P = 0.96; 1 study, 106 participants; low‐certainty evidence; <a href="./references#CD010019-fig-0009" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD010019-sec-0073"> <h6 class="title">Adverse effects such as haemodynamic instability</h6> <p>The trials did not report on adverse effects such as haemodynamic instability.</p> </section> <section id="CD010019-sec-0074"> <h6 class="title">Recurrence of pulmonary embolism</h6> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, one outpatient (1/171) and no inpatients (0/168) had a recurrent PE within 90 days (long term). There were no cases of recurrent pulmonary embolism in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. There was no clear difference between the treatment groups (RR 2.95, 95% CI 0.12 to 71.85; P = 0.51; 2 studies, 445 participants; low‐certainty evidence; <a href="./references#CD010019-fig-0010" title="">Analysis 1.6</a>). There were no events in either group regarding the short‐term recurrence of PE (analysis within 14 days). </p> </section> <section id="CD010019-sec-0075"> <h6 class="title">Patient satisfaction, adherence, or both</h6> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 156 of 170 outpatients (92%) and 158 of 167 inpatients (95%) were very satisfied or satisfied with the medical care received. In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, 29 of 48 outpatients (60%) and 37 of 59 inpatients (63%) were very satisfied with assignment to intervention or control group. There was no clear evidence to support a difference between the two interventions regarding patient satisfaction (RR 0.97, 95% CI 0.90 to 1.04; P = 0.97; 2 studies, 444 participants; <a href="./references#CD010019-fig-0011" title="">Analysis 1.7</a>). The certainty of evidence was downgraded to moderate because the effect of missing data and the absence of publication bias could not be verified. The trials did not report on adherence. </p> </section> <section id="CD010019-sec-0076"> <h6 class="title">Other analyses</h6> <p>As only two studies were included, we were unable to perform sensitivity analyses or assess the risk of publication bias. We had intended to carry out subgroup analyses as described in <a href="#CD010019-sec-0044">Subgroup analysis and investigation of heterogeneity</a>. These were also limited by the number of studies included; however, where possible, we performed subgroup analysis according to treatment regimens. For most outcomes, we were unable to check for subgroup differences due to the absence of events in one or more studies. Where data were sufficient, no subgroup differences were seen in the satisfaction levels between treatment regimens (P = 0.97; <a href="./references#CD010019-fig-0011" title="">Analysis 1.7</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010019-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010019-sec-0077"></div> <p>Outpatient treatment is the usual standard of care for most patients with acute deep venous thrombosis (DVT), whereas hospitalisation is the standard of care for most patients with acute pulmonary embolism (PE) due to different outcomes. Advances in pharmacotherapy have allowed outpatient care in low‐risk acute venous thromboembolism (VTE) (<a href="./references#CD010019-bbs2-0048" title="MansourS , AlotaibiG , WuC , McMurtryMS .Trends in admission rates and in-hospital stay for venous thromboembolism. Thrombosis Research2017;156:149-54.">Mansour 2017</a>). Compared to vitamin K antagonists, non‐vitamin K antagonist oral anticoagulants (NOACs) act on only one part of the coagulation cascade, have a prompt onset of action, fixed dosing, and few dietary and drug interactions (<a href="./references#CD010019-bbs2-0037" title="KabrhelC , VinsonDR , MitchellAM , RosovskyRP , ChangAM , Hernandez-NinoJ , et al.A clinical decision framework to guide the outpatient treatment of emergency department patients diagnosed with acute pulmonary embolism or deep vein thrombosis: results from a multidisciplinary consensus panel. Journal of the American College of Emergency Physicians2021;2(6):e12588.">Kabrhel 2021</a>). </p> <p>Although NOACs have gained approval for the management of VTE, their effect on site‐of‐care decision‐making has not yet been fully evaluated for outpatient management of PE (<a href="./references#CD010019-bbs2-0066" title="VinsonDR , MarkDG , ChettipallyUK , HuangJ , RauchwergerAS , ReedME , et al.Increasing safe outpatient management of emergency department patients with pulmonary embolism a controlled pragmatic trial. Annals of Internal Medicine2018;169(12):855-65.">Vinson 2018</a>), with early research suggesting little impact (<a href="./references#CD010019-bbs2-0041" title="KlineJA , KahlerJP , BeamDM .Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance. Patient Preference and Adherence2016;10:561-9.">Kline 2016</a>; <a href="./references#CD010019-bbs2-0062" title="SteinPD , MattaF , HughesPG , HourmouzisZN , HourmouzisNP , WhiteRM , et al.Home treatment of pulmonary embolism in the era of novel oral anticoagulants. American Journal of Medicine2016;129:974-7.">Stein 2016</a>). However, the advent of subcutaneous low molecular weight heparins (LMWH), fondaparinux and NOACs has raised the possibility of expanding the traditional in‐hospital treatment of acute PE to early discharge or complete treatment in the outpatient setting (<a href="./references#CD010019-bbs2-0040" title="KearonC , AklEA , OrnelasJ , BlaivasA , JimenezD , BounameauxH , et al.Antithrombotic therapy for VTE disease and expert panel report (10th edition). Chest2016;149(2):315-52.">Kearon 2016</a>). Regardless, the proportion of patients with acute PE receiving outpatient treatment is still low in most industrialised countries (<a href="./references#CD010019-bbs2-0057" title="RoyPM , MoumnehT , PenalozaA , Sanchez.Outpatient management of pulmonary embolism. Thrombosis Research2017;157:92-100.">Roy 2017</a>). </p> <p>There are several potential benefits of outpatient treatment of PE over traditional hospital treatment: high patient satisfaction, reduction of hospitalisations, substantial cost savings, improvement in health‐related quality of life (<a href="./references#CD010019-bbs2-0020" title="DastaJF , PilonD , ModySH , LopattoK , LalibertéG , GermainG , et al.Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. Thrombosis Research2015;135(2):303-10.">Dasta 2015</a>; <a href="./references#CD010019-bbs2-0024" title="FanikosJ , RaoA , SegerAC , CarterD , PiazzaG , GoldhaberSZ .Hospital costs of acute pulmonary embolism. American Journal of Medicine2013;126(2):127-32.">Fanikos 2013</a>), and increased physical activity and social functioning. Nevertheless, identifying patients at low risk of mortality who could benefit from outpatient management presents challenges. For many years, the lack of prognostic criteria to identify patients at low risk of mortality precluded safe outpatient management (<a href="./references#CD010019-bbs2-0065" title="VinsonDR , ZehtabchiS , YealyDM .Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review. Annals of Emergency Medicine2012;60(5):651-62.">Vinson 2012</a>; <a href="./references#CD010019-bbs2-0068" title="ZondagW , KooimanJ , KlokF , DekkersO , HuismanM .Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. European Respiratory Journal2012;42(1):134-44.">Zondag 2012</a>). </p> <p>In the RIETE Registry, fatal PE occurred in 12% of patients presenting with massive PE and in 3% of patients with non‐massive PE (<a href="./references#CD010019-bbs2-0046" title="LaporteS , MismettiP , DécoususH , UresandiF , OteroR , LoboJL , et al.Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation2008;117(13):1711-6.">Laporte 2008</a>). Therefore, most patients with acute non‐massive PE at presentation have a better prognosis and, as in patients with DVT, it is possible that treatment in a substantial proportion of these individuals can be safely managed completely, or at least partially (early discharge), as outpatients (<a href="./references#CD010019-bbs2-0051" title="OthienoR , OkpoE , ForsterR .Home versus in-patient treatment for deep vein thrombosis. Cochrane Database of Systematic Reviews2018, Issue 1. Art. No: CD003076. [DOI: 10.1002/14651858.CD003076.pub3]">Othieno 2018</a>; <a href="./references#CD010019-bbs2-0060" title="SegalJB , StreiﬀMB , HofmannLV , ThorntonK , BassEB .Management of venous thromboembolism: a systematic review for a practice. Annals of Internal Medicine2007;146(3):211-22.">Segal 2007</a>). Although not based on high‐certainty evidence, two retrospective cohort studies, <a href="./references#CD010019-bbs2-0023" title="ErkensPM , Gandara, WellsP , ShenAY , BoseG , Le GalG , et al.Safety of outpatient treatment in acute pulmonary embolism. Journal of Thrombosis and Haemostasis2010;8:2412-7.">Erkens 2010</a> and <a href="./references#CD010019-bbs2-0044" title="KovacsMJ , HawelJD , RekmanJF , Lazo-LangnerA .Ambulatory management of pulmonary embolism: a pragmatic evaluation. Journal of Thrombosis and Haemostasis2010;8(11):2406-11.">Kovacs 2010</a>, showed that at least 50% of patients presenting with symptomatic PE can be treated safely as outpatients. </p> <p>Treating acute PE in the outpatient setting in carefully selected patients has been allowed and studied in Europe and Canada more than in the USA. In some hospitals in Canada, about 50% of people with acute PE are managed entirely as outpatients (<a href="./references#CD010019-bbs2-0012" title="BaglinT .Fifty per cent of patients with pulmonary embolism can be treated as outpatients. Journal of Thrombosis and Haemostasis2010;8(11):2404-5.">Baglin 2010</a>; <a href="./references#CD010019-bbs2-0044" title="KovacsMJ , HawelJD , RekmanJF , Lazo-LangnerA .Ambulatory management of pulmonary embolism: a pragmatic evaluation. Journal of Thrombosis and Haemostasis2010;8(11):2406-11.">Kovacs 2010</a>). Conversely, based on the report of the Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry (EMPEROR) (<a href="./references#CD010019-bbs2-0054" title="PollackCV , SchreiberD , Goldhaber SZ, SlatteryD , FanikosJ , O'NeilBJ , et al.Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). Journal of the American College of Cardiology2011;57(6):700-6.">Pollack 2011</a>), in the USA only 1.1% of people attending the emergency department were discharged home without hospitalisation. Several factors might explain this geographic discrepancy, such as issues of health insurance compensation and malpractice litigation (<a href="./references#CD010019-bbs2-0065" title="VinsonDR , ZehtabchiS , YealyDM .Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review. Annals of Emergency Medicine2012;60(5):651-62.">Vinson 2012</a>). </p> <p>The 2014 European Society of Cardiology (ESC) guidelines suggested considering early discharge and outpatient management in patients judged as having low‐risk PE (<a href="./references#CD010019-bbs2-0042" title="KonstantinidesS , TorbickiA , AgnelliG , DanchinN , FitzmauriceD , GalièN , et al.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal2014;35(43):3033–73. [DOI: 10.1093/eurheartj/ehu283]">Konstantinides 2014</a>). Nevertheless, due to insufficient evidence, there is no clear recommendation of whether the Pulmonary Embolism Severity Index (PESI) or the Hestia criteria are more appropriate for determining the safe setting for treatment. </p> <p>The 2018 guideline from the British Thoracic Society recommended that patients with confirmed PE should be risk‐stratified using a validated clinical risk score (<a href="./references#CD010019-bbs2-0031" title="HowardLS , BardenS , CondliffeR , ConnollyV , DaviesCW , DonaldsonJ , et al.British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax2018;73:ii1-ii29. doi:10.1136/thoraxjnl-2018-211539.">Howard 2018</a>). Patients in PESI class I/II, sPESI class 0, or those meeting the Hestia criteria should be considered for outpatient management of PE. More recently, NICE proposed a similar recommendation considering outpatient treatment in patients with low‐risk PE, using a validated risk‐stratification tool (<a href="./references#CD010019-bbs2-0050" title="National Institute for Health and Care Excellence (NICE).Venous thromboembolic diseases: diagnosis, management and thrombophilia testing NG158. nice.org.uk/guidance/ng158 (accessed 16 February 2022).">NICE 2020</a>). </p> <p>Two prospective studies in the USA, which used the PESI to identify patients eligible for outpatient management, have shown outpatient management to be safe and effective in selected low‐risk patients with PE (<a href="./references#CD010019-bbs2-0017" title="BledsoeJ , WollerS , StevensS , AstonV , PattenR , AllenT , et al.Management of low-risk pulmonary embolism (LoPE) patients without hospitalization: the LoPE prospective management study. Chest2018;154(2):249-56.">Bledsoe 2018</a>; <a href="./references#CD010019-bbs2-0066" title="VinsonDR , MarkDG , ChettipallyUK , HuangJ , RauchwergerAS , ReedME , et al.Increasing safe outpatient management of emergency department patients with pulmonary embolism a controlled pragmatic trial. Annals of Internal Medicine2018;169(12):855-65.">Vinson 2018</a>). <a href="./references#CD010019-bbs2-0066" title="VinsonDR , MarkDG , ChettipallyUK , HuangJ , RauchwergerAS , ReedME , et al.Increasing safe outpatient management of emergency department patients with pulmonary embolism a controlled pragmatic trial. Annals of Internal Medicine2018;169(12):855-65.">Vinson 2018</a> employed the prediction score flexibly, in that the PESI class was not strictly tied to a site‐of‐care disposition. Rather, the risk class was used to inform clinical judgement, not direct it. This more flexible use of the PESI is endorsed by the American College of Chest Physicians in their recent PE guideline (<a href="./references#CD010019-bbs2-0040" title="KearonC , AklEA , OrnelasJ , BlaivasA , JimenezD , BounameauxH , et al.Antithrombotic therapy for VTE disease and expert panel report (10th edition). Chest2016;149(2):315-52.">Kearon 2016</a>). </p> <p>Whether the prompt echocardiographic assessment of right ventricular dysfunction (RVD) is essential to select PE patients for outpatient treatment is still a matter of debate (<a href="./references#CD010019-bbs2-0016" title="BecattiniC , AgnelliG .Acute treatment of venous thromboembolism. Blood2020;135(5):305-16.">Becattini 2020</a>). According to a review and meta‐analysis by <a href="./references#CD010019-bbs2-0013" title="BarcoS , MahmoudpourSH , PlanquetteB , SanchezO , KonstantinidesSV , MeyerG .Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. European Heart Journal2019;40(11):902-10.">Barco 2019</a>, 34% (95% CI 30% to 39%) of patients classified as being as low risk by the PESI, sPESI, or the Hestia criteria were reported to have signs of RVD on echocardiography or computed tomography pulmonary angiogram. The presence of RVD was associated with a four‐fold increased risk of death, but the absolute risk for death was low in patients with versus without RVD on echocardiography: 1.8% (95% CI 0.9% to 3.5%) compared to 0.2% (95% CI 0.03% to 1.7%), respectively (OR 4.19, 95% CI 1.39 to 12.58) (<a href="./references#CD010019-bbs2-0013" title="BarcoS , MahmoudpourSH , PlanquetteB , SanchezO , KonstantinidesSV , MeyerG .Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. European Heart Journal2019;40(11):902-10.">Barco 2019</a>). <a href="./references#CD010019-bbs2-0016" title="BecattiniC , AgnelliG .Acute treatment of venous thromboembolism. Blood2020;135(5):305-16.">Becattini 2020</a> concluded that "right ventricle assessment would preclude about 34% of low‐risk patients from early discharge (95% CI 30% to 39%) to potentially identify 1.8% that will die or 3.5% that will experience a PE‐related adverse outcome." </p> <p>The 2019 ESC Guidelines recommended considering early discharge of patients with acute PE and continuation of anticoagulant therapy at home if three sets of criteria are met (<a href="./references#CD010019-bbs2-0043" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al.2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Respiratory Journal2019;54(3):1901647.">Konstantinides 2019</a>). </p> <p> <ol id="CD010019-list-0011"> <li> <p>The risk of early PE‐related death or serious complications is low.</p> </li> <li> <p>There is no serious comorbidity or aggravating condition(s) that would demand hospitalisation.</p> </li> <li> <p>Proper outpatient care and anticoagulant therapy can be provided, considering the patient’s (anticipated) compliance and the possibilities offered by the healthcare system and social infrastructure. </p> </li> </ol> </p> <p>Similarly, the recently published update of the Chest Guideline and Expert Panel Report recommends outpatient treatment rather than hospitalisation in low‐risk PE patients, provided that access to medication, the ability to access outpatient care, and the home conditions are appropriate (<a href="./references#CD010019-bbs2-0063" title="StevensSM , WollerSC , Baumann KreuzigerL , BounameauxH , DoerschugK , GeersingGJ , et al.Executive Summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report. Chest2021;160(6):2247-59.">Stevens 2021</a>). </p> <p>The multidisciplinary consensus panel of the American College of Emergency Physicians provided a robust recommendation to help clinicians safely treat low‐risk PE outpatients (<a href="./references#CD010019-bbs2-0037" title="KabrhelC , VinsonDR , MitchellAM , RosovskyRP , ChangAM , Hernandez-NinoJ , et al.A clinical decision framework to guide the outpatient treatment of emergency department patients diagnosed with acute pulmonary embolism or deep vein thrombosis: results from a multidisciplinary consensus panel. Journal of the American College of Emergency Physicians2021;2(6):e12588.">Kabrhel 2021</a>). After confirmed diagnosis of PE, the next step is risk stratifying the patient to assess whether outpatient treatment is suitable. This assessment takes into account the following conditions: risk of bleeding from anticoagulation, access to the medication in a timely manner, and patient's psychosocial condition for early discharge. Then, regular follow‐up is essential, and the patient must also be informed about the warning signs or symptoms that should prompt a return to the emergency department. </p> <p>In this 2022 Cochrane Review, we included only two randomised controlled trials that compared outpatient versus inpatient management of acute PE (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>; <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>). <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> used the PESI, a validated risk‐stratification instrument, to select low‐risk patients who were eligible for outpatient treatment. These results suggest a feasible perspective on the safety of PE management in an outpatient setting. <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> reported preliminary results using the Hestia criteria to select low‐risk PE patients who can be safely and effectively managed as outpatients with rivaroxaban. The results between outpatient versus inpatient groups for mortality, thromboembolic events and haemorrhagic complications were similarly very low in both groups. No clear differences were detected between the outpatient and inpatient groups for the outcomes of mortality, bleeding, recurrent PE and patient satisfaction. Seemingly both methods for selection of low‐risk PE patients (PESI and Hestia) can be applied with acceptable outcomes. A scientific comparison of the two methods in which patients were randomised to either the sPESI or Hestia criteria was recently completed, showing similar safety and effectiveness for triaging patients with acute PE for outpatient treatment (<a href="./references#CD010019-bbs2-0004" title="RoyPM , GableB .Hospitalization or Out-treatment ManagEment of Patients with Pulmonary Embolism: a randomized controlled trial (HOME-PE). clinicaltrials.gov/ct2/show/NCT02811237 (first received 23 June 2016). ">HOME Study</a>; <a href="./references#CD010019-bbs2-0058" title="RoyPM , PenalozaA , HugliO , KlokFA , ArnouxA , EliasA , et al.Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. European Heart Journal2021;42(33):3146-57.">Roy 2021</a>). </p> <p>Further large, randomised studies are required to provide information on the selection of low‐risk PE patients for outpatient management. It is currently unclear whether the PESI or the Hestia criteria are more accurate for identifying suitable outpatients, whether troponin levels have to be considered for safe selection of these patients, or whether imaging such as echocardiogram and compression ultrasonography of the leg veins are also necessary. </p> <section id="CD010019-sec-0078"> <h3 class="title" id="CD010019-sec-0078">Summary of main results</h3> <p>This review examined the effects of outpatient versus inpatient treatment in low‐risk patients with acute PE. We included two RCTs, involving 453 participants, that reported our primary outcomes. In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, inpatients and outpatients received the same treatment regimens (enoxaparin 1 mg/kg twice daily); and in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, inpatients were treated with rivaroxaban 15 mg and outpatients with the local standard of care. No deaths occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, and two deaths occurred in <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, one in each group. For short‐ and long‐term mortality, major and minor bleeding, and recurrent PE there was no clear evidence of a difference between the treatment groups, as there was imprecision in the results (the numbers of events were very small, the confidence intervals were wide and included treatment effects in both directions, and the certainty of the evidence was low). See <a href="./full#CD010019-tbl-0001">summary of findings Table 1</a>. There was no clear evidence to support a difference between the two interventions regarding patient satisfaction: 92% and 60% of outpatients, and 95% and 63% of inpatients, were very satisfied or satisfied with the medical care received (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> and <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, respectively). The included studies did not assess adverse effects such as haemodynamic instability or adherence to treatment. </p> </section> <section id="CD010019-sec-0079"> <h3 class="title" id="CD010019-sec-0079">Overall completeness and applicability of evidence</h3> <p>Because of our comprehensive search strategy and contact with experts in the field, we are confident that we have identified all RCTs and quasi‐RCTs comparing outpatient versus inpatient treatment for acute PE. This review addresses the non‐inferiority hypothesis that outpatient treatment presents the same benefits as inpatient treatment for acute PE. Outpatient treatment can improve health‐related quality of life and reduce hospitalisation rates and costs, although outpatient treatment will incur some health service costs. A key point concerning this clinical question is the appropriate selection of people who are at low risk. More studies are needed to assess the accuracy of the PESI for identifying a population of low‐risk patients who can be safely and effectively treated without hospitalisation. The PESI, as used by <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, consists of 11 routinely available clinical parameters based on signs and symptoms, and it stratifies patients into five risk classes (I to V) at an increasing risk of short‐term mortality (<a href="./appendices#CD010019-sec-0090">Appendix 2</a>). The validation study of PESI performed by <a href="./references#CD010019-bbs2-0011" title="AujeskyD , PerrierA , RoyPM , StoneRA , CornuzJ , MeyerG , et al.Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. Journal of Internal Medicine2007;261(6):597-604.">Aujesky 2007</a> identified low‐risk patients who are potential candidates for outpatient treatment, with very low rates of 90‐day all‐cause mortality (1% or less). <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> used the Hestia criteria (see <a href="./appendices#CD010019-sec-0092">Appendix 4</a>), which consist of 11 practical clinical exclusion rules to select patients for outpatient treatment. The Hestia criteria were later validated in 550 patients by combining them with a 500 ng/L cutoff for NT‐proBNP levels to select patients for outpatient treatment (<a href="./references#CD010019-bbs2-0022" title="den ExterPL , ZondagW , KlokFA , BrouwerRE , DolsmaJ , EijsvogelM , et al.Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without N-terminal pro–brain natriuretic peptide testing in patients with acute pulmonary embolism. American Journal of Respiratory and Critical Care Medicine2016;194(8):998-1006.">Den Exter 2016b</a>). Although in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, the inpatients and outpatients received different treatment regimens, local standard of care also involved rivaroxaban. Regardless of the different treatment regimens between groups, there was no difference in results. Neither study reported on all our predefined outcomes, such as haemodynamic instability or adherence. We excluded one RCT from this review because it used a different definition for outpatients (early discharge was considered as discharge after three to five days of admission (<a href="./references#CD010019-bbs2-0007" title="OteroR , UresandiF , JiménezD , CabezudoMA , OribeM , NauffalD , et al.Home treatment in pulmonary embolism. Thrombosis Research2010;126(1):e1-5. ">Otero 2010</a>), compared with less than 36 hours in <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> and <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>). In addition, <a href="./references#CD010019-bbs2-0007" title="OteroR , UresandiF , JiménezD , CabezudoMA , OribeM , NauffalD , et al.Home treatment in pulmonary embolism. Thrombosis Research2010;126(1):e1-5. ">Otero 2010</a> used a non‐validated clinical prognostic model to identify low‐risk patients. </p> </section> <section id="CD010019-sec-0080"> <h3 class="title" id="CD010019-sec-0080">Quality of the evidence</h3> <p>The overall certainty of the evidence for the primary outcomes of short‐ and long‐term mortality was low (<a href="./full#CD010019-tbl-0001">summary of findings Table 1</a>). We downgraded our assessments of the certainty of evidence due to the small number of participants and events and imprecision. In addition, we were unable to discount publication bias (<a href="./references#CD010019-bbs2-0027" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck-YtterY , SchunemannHJ .What is "quality of evidence" and why is it important to clinicians?BMJ2008;336:995-8.'>Guyatt 2008</a>). It is therefore difficult to draw robust conclusions on the basis of the available evidence. </p> </section> <section id="CD010019-sec-0081"> <h3 class="title" id="CD010019-sec-0081">Potential biases in the review process</h3> <p>One area of potential bias in this review is the weakness of statistical power because of the small number of included studies. Although we performed a well‐designed search strategy to identify all potential studies, we found only two RCTs that met the eligibility criteria, which makes our findings uncertain, as larger trials are needed to detect a difference (or determine there is no meaningful difference) between inpatient and outpatient care. </p> <p>In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> the outpatient group received rivaroxaban, and the inpatient group received standard of care (treatment based on local institutional protocols, which may include admission, a parenteral anticoagulant and an oral vitamin K antagonist, or any of the NOACs). This is different from <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, which had similar pharmacological treatments in the inpatient and outpatient treatment arms. We decided to include <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> because in the inpatient group 50.8% of patients received rivaroxaban, and the results for the primary outcomes between <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> and <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> were quite similar (low number of events). We recognise the importance and methodological rigour of <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>; however, <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> appears to be more pragmatic, so we considered it important to include and to pool the data. In order to highlight any potential differences, we performed a subgroup analysis (inpatients and outpatients with same treatment regimens versus inpatients and outpatients treated with different treatment regimens). <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a> used the Hestia criteria to classify patients, so we considered that most patients were symptomatic. </p> </section> <section id="CD010019-sec-0082"> <h3 class="title" id="CD010019-sec-0082">Agreements and disagreements with other studies or reviews</h3> <p>We found one systematic review that selected observational studies, including prospective cohort studies that described the outcome of people with PE treated entirely as outpatients (<a href="./references#CD010019-bbs2-0065" title="VinsonDR , ZehtabchiS , YealyDM .Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review. Annals of Emergency Medicine2012;60(5):651-62.">Vinson 2012</a>). The review examined the results of exclusive ambulatory management for people with acute symptomatic PE. However, the authors considered an observational period of less than 24 hours, that is, the review did not consider inpatient stay followed by early discharge. The review also indicated that both treatments had similar effectiveness. Hence, <a href="./references#CD010019-bbs2-0065" title="VinsonDR , ZehtabchiS , YealyDM .Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review. Annals of Emergency Medicine2012;60(5):651-62.">Vinson 2012</a> recommended that patients with a low risk of adverse clinical outcomes (e.g. mortality, recurrence and bleeding) be treated as outpatients due to the advantages of low cost, avoidance of hospital infections, and high levels of patient satisfaction (<a href="./references#CD010019-bbs2-0065" title="VinsonDR , ZehtabchiS , YealyDM .Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review. Annals of Emergency Medicine2012;60(5):651-62.">Vinson 2012</a>). </p> <p><a href="./references#CD010019-bbs2-0061" title="SquizzatoA , GalliM , DentaliF , AgenoW .Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review. European Respiratory Journal2009;33(5):1148-55.">Squizzato 2009</a> also conducted a systematic review that evaluated the effects of outpatient treatment for PE. All the included studies were observational studies, and the authors concluded that patients might be safely treated as outpatients. The authors recommended further studies to confirm or refute these findings. </p> <p>Three systematic reviews included observational studies and RCTs (including <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, which we also included, and <a href="./references#CD010019-bbs2-0007" title="OteroR , UresandiF , JiménezD , CabezudoMA , OribeM , NauffalD , et al.Home treatment in pulmonary embolism. Thrombosis Research2010;126(1):e1-5. ">Otero 2010</a>, which we excluded). The reviews evaluated whether outpatient treatment and early discharge were as safe as conventional inpatient treatment in people with acute PE (<a href="./references#CD010019-bbs2-0052" title="PiranS , GalGL , WellsP , RighiniM , CarrierM .Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. Blood (ASH Annual Meeting Abstracts)2012;120:361.">Piran 2012</a>; <a href="./references#CD010019-bbs2-0053" title="PiranS , Le GalG , WellsPS , GandaraE , RighiniM , RodgerMA , et al.Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. Thrombosis Research2013;132(5):515-9.">Piran 2013</a>; <a href="./references#CD010019-bbs2-0068" title="ZondagW , KooimanJ , KlokF , DekkersO , HuismanM .Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. European Respiratory Journal2012;42(1):134-44.">Zondag 2012</a>). Although heterogeneous criteria were used to select participants, the results showed that in a carefully selected group classified as being at low risk, both treatments were equally safe; this conclusion is in agreement with the findings of our systematic review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010019-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010019-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Screen4Me flow diagram" data-id="CD010019-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Screen4Me flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD010019-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD010019-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Outpatient versus inpatient treatment, Outcome 1: Short‐term all‐cause mortality" data-id="CD010019-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Outpatient versus inpatient treatment, Outcome 1: Short‐term all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#CD010019-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Outpatient versus inpatient treatment, Outcome 2: Long‐term all‐cause mortality" data-id="CD010019-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Outpatient versus inpatient treatment, Outcome 2: Long‐term all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#CD010019-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Outpatient versus inpatient treatment, Outcome 3: Major bleeding within 14 days" data-id="CD010019-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Outpatient versus inpatient treatment, Outcome 3: Major bleeding within 14 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#CD010019-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Outpatient versus inpatient treatment, Outcome 4: Major bleeding within 90 days" data-id="CD010019-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Outpatient versus inpatient treatment, Outcome 4: Major bleeding within 90 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#CD010019-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Outpatient versus inpatient treatment, Outcome 5: Minor bleeding" data-id="CD010019-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Outpatient versus inpatient treatment, Outcome 5: Minor bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#CD010019-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Outpatient versus inpatient treatment, Outcome 6: Recurrent pulmonary embolism within 90 days" data-id="CD010019-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Outpatient versus inpatient treatment, Outcome 6: Recurrent pulmonary embolism within 90 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#CD010019-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010019-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/urn:x-wiley:14651858:media:CD010019:CD010019-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Outpatient versus inpatient treatment, Outcome 7: Satisfaction questionnaire" data-id="CD010019-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_t/tCD010019-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Outpatient versus inpatient treatment, Outcome 7: Satisfaction questionnaire</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#CD010019-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/media/CDSR/CD010019/image_n/nCD010019-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010019-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Outpatient versus inpatient treatment for acute pulmonary embolism</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Outpatient versus inpatient treatment for acute pulmonary embolism</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with low‐risk acute pulmonary embolism </p> <p><b>Settings</b>: outpatient and inpatient settings </p> <p><b>Intervention</b>: outpatient setting<sup>a</sup> </p> <p><b>Comparison</b>: inpatient setting<sup>b</sup> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with inpatient setting</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with outpatient setting</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term all‐cause mortality</b> </p> <p>Follow‐up: 7 to 10 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred in either study within this time period.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Short‐term all‐cause mortality</b> </p> <p>Follow‐up: to 30 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 0.33 (0.01 to 7.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>453 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 1/168 deaths in the inpatient group vs 0/171 deaths in the outpatient group. The death reported by <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> was not PE‐related. No deaths occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000 (0 to 35)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Long‐term all‐cause mortality</b> </p> <p>Follow‐up: 90 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 0.98 (0.06 to 15.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>451<sup>e</sup> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 1/168 deaths in the inpatient group vs 1/171 deaths in the outpatient group. The deaths reported by <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a> were not PE‐related. No deaths occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (0 to 68)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b> </p> <p>Follow‐up: 14 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 4.91 (0.24 to 101.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 0/168 major bleeding events in the inpatient group vs 2/171 major bleeding events in the outpatient group. No major bleeding occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b> </p> <p>Follow‐up: 90 days after randomisation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 6.88 (0.36 to 132.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 0/168 major bleeding events in the inpatient group vs 3/171 major bleeding events in the outpatient group. No major bleeding occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor bleeding</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 1.08 (0.07 to 16.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>106 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One participant in each treatment arm reported minor bleeding.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000 (1 to 305)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrent PE</b> </p> <p>Follow‐up: within 90 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 2.95 (CI 0.12 to 71.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, 0/168 recurrent PE in inpatient group vs 1/171 recurrent PE in the outpatient group, within 90 days. No recurrent PE occurred in <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>PE</b>: pulmonary embolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Outpatients received subcutaneous enoxaparin twice daily (<a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>), or rivaroxaban 15 mg orally twice daily for the first 21 days, followed by 20 mg orally once daily for approximately 69 days, for a total treatment duration of 90 days (<a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>).<br/><sup>b</sup>In <a href="./references#CD010019-bbs2-0001" title="AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.An international, randomized non-inferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine2011;26(10):1220. AujeskyD , RoyPM , VerschurenF , RighiniM , OsterwalderJ , EgloffM , et al.Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet2011;378(9785):41-8. ">Aujesky 2011</a>, the inpatient group was admitted to hospital and received subcutaneous enoxaparin 1 mg/kg twice daily. In <a href="./references#CD010019-bbs2-0002" title="NCT02584660.A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department (MERCURY PE). clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockWF , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al.Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. SingerAJ , XiangJ , KabrhelC , MerliGJ , PollackC , TapsonVF , et al.MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE): rationale and design. Academic Emergency Medicine2016;23(11):1280-6. ">Peacock 2018</a>, the inpatient group was admitted to hospital and received variable pharmacotherapy (standard‐of‐care treatment).<br/><sup>c</sup>We downgraded by two levels as the small sample size means it is unlikely that rare events will be seen and because publication bias could not be discounted.<br/><sup>d</sup>We downgraded by two levels due to the overall small sample size, small number of events, imprecision in the confidence intervals and the fact that publication bias could not be discounted.<br/><sup>e</sup>Additional information was requested from the study authors, but as they were unable to provide it, we used only the available data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Outpatient versus inpatient treatment for acute pulmonary embolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/full#CD010019-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010019-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Outpatient versus inpatient treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Short‐term all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Inpatients and outpatients with same treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Inpatients and outpatients treated with different treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Long‐term all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Inpatients and outpatients with same treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Inpatients and outpatients treated with different treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Major bleeding within 14 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.91 [0.24, 101.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Inpatients and outpatients with same treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.91 [0.24, 101.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Inpatients and outpatients treated with different treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Major bleeding within 90 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.88 [0.36, 132.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Inpatients and outpatients with same treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.88 [0.36, 132.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Inpatients and outpatients treated with different treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.07, 16.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Recurrent pulmonary embolism within 90 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.12, 71.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Inpatients and outpatients with same treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.12, 71.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Inpatients and outpatients treated with different treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Satisfaction questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Inpatients and outpatients treated with same treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.92, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Inpatients and outpatients with different treatment regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.71, 1.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Outpatient versus inpatient treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010019.pub4/references#CD010019-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010019.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010019-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010019-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010019-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010019-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010019-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD010019-note-0005">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010019-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010019\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010019\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010019\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010019\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010019\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010019.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010019.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010019.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010019.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010019.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714945014"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010019.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714945018"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010019.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7b0ccf439368',t:'MTc0MDcxNDk0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 